Skip to content
10-Q

Quarterly Report

ENANTA PHARMACEUTICALS INC ENTA

0001193125-26-220572

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · May 5, 2026 29.08M sh
Shares Diluted Q2 2026 · Mar 31, 2026 29.04M sh
Shares Diluted Q2 2026 · Mar 31, 2026 28.89M sh
Shares Diluted Q2 2026 · Mar 31, 2025 21.36M sh
Shares Diluted Q2 2026 · Mar 31, 2025 21.3M sh
Capex Q2 2026 · Mar 31, 2026 $158K
Capex Q2 2026 · Mar 31, 2025 $11.28M
Operating Cash Flow Q2 2026 · Mar 31, 2026 −$18.86M
Operating Cash Flow Q2 2026 · Mar 31, 2025 −$30.29M
Cash And Equivalents Q2 2026 · Mar 31, 2026 $34.93M
Cash And Equivalents Q2 2026 · Sep 30, 2025 $32.3M
Stockholders Equity Q2 2026 · Mar 31, 2026 $116.59M
Stockholders Equity Q2 2026 · Dec 31, 2025 $126.59M
Stockholders Equity Q2 2026 · Sep 30, 2025 $64.72M
Stockholders Equity Q2 2026 · Mar 31, 2025 $93.54M
Stockholders Equity Q2 2026 · Dec 31, 2024 $111.82M
Stockholders Equity Q2 2026 · Sep 30, 2024 $128.81M
Current Liabilities Q2 2026 · Mar 31, 2026 $46.44M
Current Liabilities Q2 2026 · Sep 30, 2025 $48.56M
Total Liabilities Q2 2026 · Mar 31, 2026 $198.12M
Total Liabilities Q2 2026 · Sep 30, 2025 $216.02M
Current Assets Q2 2026 · Mar 31, 2026 $178.41M
Current Assets Q2 2026 · Sep 30, 2025 $204.34M
Total Assets Q2 2026 · Mar 31, 2026 $314.7M
Total Assets Q2 2026 · Sep 30, 2025 $280.73M
Eps Diluted Q2 2026 · Mar 31, 2026 −$0.45
Eps Diluted Q2 2026 · Mar 31, 2026 −$0.87
Eps Diluted Q2 2026 · Mar 31, 2025 −$1.06
Eps Diluted Q2 2026 · Mar 31, 2025 −$2.11
Eps Basic Q2 2026 · Mar 31, 2026 −$0.45
Eps Basic Q2 2026 · Mar 31, 2026 −$0.87
Eps Basic Q2 2026 · Mar 31, 2025 −$1.06
Eps Basic Q2 2026 · Mar 31, 2025 −$2.11
Sga Expense Q2 2026 · Mar 31, 2026 $9.57M
Sga Expense Q2 2026 · Mar 31, 2026 $18.58M
Sga Expense Q2 2026 · Mar 31, 2025 $11.39M
Sga Expense Q2 2026 · Mar 31, 2025 $24.23M
Rd Expense Q2 2026 · Mar 31, 2026 $19.44M
Rd Expense Q2 2026 · Mar 31, 2026 $40.3M
Rd Expense Q2 2026 · Mar 31, 2025 $28.07M
Rd Expense Q2 2026 · Mar 31, 2025 $55.72M
Net Income Q2 2026 · Mar 31, 2026 −$13.09M
Net Income Q2 2026 · Mar 31, 2026 −$25.03M
Net Income Q2 2026 · Dec 31, 2025 −$11.94M
Net Income Q2 2026 · Sep 30, 2025 −$81.89M
Net Income Q2 2026 · Mar 31, 2025 −$22.64M
Net Income Q2 2026 · Mar 31, 2025 −$44.93M
Net Income Q2 2026 · Dec 31, 2024 −$22.29M
Operating Income Q2 2026 · Mar 31, 2026 −$11.85M
Operating Income Q2 2026 · Mar 31, 2026 −$23.11M
Operating Income Q2 2026 · Mar 31, 2025 −$24.53M
Operating Income Q2 2026 · Mar 31, 2025 −$48.07M
Revenue Q2 2026 · Mar 31, 2026 $17.16M
Revenue Q2 2026 · Mar 31, 2026 $35.77M
Revenue Q2 2026 · Mar 31, 2025 $14.93M
Revenue Q2 2026 · Mar 31, 2025 $31.89M